(Reuters) – An AstraZeneca Plc executive said the British drugmaker would consider not submitting its COVID-19 vaccine for approval in the United States if the regulatory process takes too long, the Financial Times reported on Thursday.
The company’s research and development head, Mene Pangalos, said AstraZeneca would instead focus its attention on selling the vaccine in other countries, though it will continue to talk to the U.S. Food and Drug Administration, according to the report. AstraZeneca did not immediately respond to a Reuters request for comment.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Devika Syamnathy)
